Just a quick note about this. See below for the CAPRA trial:
Have bolded "eight" for emphasis. Viralytics are scheduled to present five posters at SITC 2016. Only the abstract titles have been published on the site so there's no telling if they're the same posters as the ESMO posters or not.
The SITC 2016 CAPRA-related poster is named as "Interim results of the CAPRA clinical trial: CAVATAK and pemrolizumab in advanced melanoma". I have a feeling we may receive more quantitative information about how the trial has progressed since there are already eight evaluable patients noted in today's announcement. This is only a hunch though based on the specific words "interim results" in the title.
- Forums
- ASX - By Stock
- VLA
- Ann: VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX
Ann: VLA update on CAVATAK KEYTRUDA Combination trials - ESMO-VLA.AX, page-2
-
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
TON
TRITON MINERALS LTD
Adrian Costello, Executive Director
Adrian Costello
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online